Navigation Links
Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
Date:2/4/2008

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, Feb. 4 /PRNewswire-FirstCall/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it has received notice from the FDA that, due to GLP deviations the 6-month inhalation toxicology studies were deemed invalid. No toxicological reasons were cited. We are currently evaluating several alternative remedies and are confident that the submission for regulatory approval will not be delayed by more than 6 months.

Conference call information:

Akela will host a conference call at 9:00 am, on Monday February 4, 2008. Interested parties may also access the conference call by webcast at http://www.akelapharma.com.

The telephone numbers to access the conference call are 1-800-732-9303 or 416-644-3415. A replay of the call will be available until February 11, 2008. The telephone numbers to access the replay are 416-640-1917 and 1-877-289-8525 with code number 21262067#.

About Akela Pharma Inc.:

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation and pain markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 11.7 million shares outstanding.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of Akela Pharma Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


'/>"/>
SOURCE Akela Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Akela Pharma provides corporate update
2. Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial
3. Akela Pharma reports results for third quarter of fiscal 2007
4. AKELA Pharma Inc. announces U.S. public offering and proposed listing
5. Akela Pharma Inc. Completes Share Consolidation
6. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
7. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
8. Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
9. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
10. West Hollywood: AHF Hosts Grand Opening of HIV/AIDS Pharmacy that Benefits AIDS Patients Worldwide
11. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... CARMEL, IN (PRWEB) , ... August 18, 2017 , ... ... 36th annual list, the most prestigious ranking of the nation's fastest-growing private companies. This ... in the exclusive Inc. 5000 ranking . This year’s ranking reflects ASH’s 76 ...
(Date:8/18/2017)... ... ... “Our Mountains to Climb: A Journey of Love and Faith Through Trials”: ... the faith they shared to overcome struggles in life. “Our Mountains to Climb: A ... J. Corcoran, a retired teacher and happily married since 1999; the author’s personal experiences ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Three Narrow Roads”: ... is the creation of published author, Rev. Dr. Burnett King Sr., is currently the ... and founder of the Faith Track Club, Inc., a track-and-field program geared towards youth. ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Depressed: Super Heroes of the Bible”: ... reflect upon the stories and the relevance these tales may have on the reader’s ... Linhart, a former special education teacher, Jessica spends much of her time enjoying nature ...
(Date:8/18/2017)... ... ... “Kingdom Mandate for Kingdom Builders”: a call to walk as citizens of the Kingdom ... of published author, John F. McGeorge, Jr. Dr. John F. McGeorge Jr., B.A., ... spent three decades training pastors and Christian leaders. He also met his wife, ...
Breaking Medicine News(10 mins):
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and other ... up healthcare costs and threatening outcomes, were problems taken ... and IVD industry that support them, met this week. ... researcher said that drugs of abuse, procalcitonin and acute ... at the organization,s 69th meeting in San ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital in ... team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, Tru-D ... UVC light energy to kill deadly pathogens such as C. diff , MRSA, MERS, ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/2/2017)... a next-generation full-service pharmacy, has announced the launch of its ... Washington D.C. metropolitan area. CaryRx aims to ... through the convenience of its patient-friendly mobile app. Prescriptions can ... to any location in D.C. ... Washington D.C. ," says Areo Nazari , ...
Breaking Medicine Technology: